Efficacy and Safety of Carbetocin Versus Misoprostol in Cesarean Section: A Systematic Review and Meta-Analysis.

Autor:	Albazee E; Department of Internship, Kuwait Institute for Medical Specializations, Kuwait City, KWT., Sadan M; Department of Internship, Kuwait Institute for Medical Specializations, Kuwait City, KWT., Alenezi AM; Department of Internship, Kuwait Institute for Medical Specializations, Kuwait City, KWT., Almutairi AN; Department of Internship, Kuwait Institute for Medical Specializations, Kuwait City, KWT., Alenezi MM; General Medicine, Alsabah Hospital, Kuwait, KWT., Almonayea LE; Department of Internship, Kuwait Institute for Medical Specializations, Kuwait City, KWT.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Dec 24; Vol. 14 (12), pp. e32901. Date of Electronic Publication: 2022 Dec 24 (Print Publication: 2022).
DOI:	10.7759/cureus.32901
Abstrakt:	In the absence of comprehensive data investigating carbetocin versus misoprostol for reducing postpartum hemorrhage (PPH) during cesarean section (CS), we performed this investigation to compare the efficiency and side events of carbetocin versus misoprostol in the protection and reduction of PPH for women who underwent CS. From inception to September 2022, we depended on searching through various databases for eligible trials involving Cochrane, Web of Science, PubMed, Scopus, and Google Scholar. From the efficacy prospect, we found that carbetocin substantially decreased intraoperative blood loss (p<0.001), hemoglobin/hematocrit levels (p<0.001), and the need for blood transfusion (p=0.002)/additional surgical interventions (p=0.003) than misoprostol. However, we revealed no substantial variation between both drugs for the need for additional uterotonic agents (p=0.08). From the safety prospect, we found that incidences of fever (p=0.002), heat sensation (p=0.007), metallic taste (p=0.01), and shivering (p=0.0002) were lower in carbetocin administration than in misoprostol. However, headache (p=0.34) and palpitation (p=0.11) incidences revealed no substantial variation between both drugs. In conclusion, from the efficacy and safety prospect, for women who underwent CS, carbetocin is more effective and safer in preventing and reducing PPH than misoprostol. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Albazee et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu